ICARE Social Media Post November 2020

ASCO Guideline Updates: Breast Cancer

The American Society of Clinical Oncology (ASCO) published updated guidelines for the management of hereditary breast cancer for the following gene carriers:
 
𝘽𝙍𝘾𝘼1/2
• Consider breast-conserving therapy
• Consider nipple-sparing mastectomy, if medically appropriate
• Advanced breast cancer:
⫸ PARP inhibitors (olaparib, talazoparib) preferred over non-platinum single agent chemotherapy
⫸ Platinum agents are recommended versus taxanes
𝙏𝙋53
• Mastectomy is advised
• Radiation therapy is contraindicated except for those at risk for locoregional recurrence
 
For more information, check out the full article at: https://ascopubs.org/doi/full/10.1200/JCO.20.00299